ETHzilla Incoming: 180 Life Sciences Goes All-In on Ethereum With $425 Million Funding

180 Life Sciences Corp. (Nasdaq: ATNF) has announced a major strategic pivot, raising $425 million through a PIPE (private investment in public equity). This is to fund an ethereum-focused treasury strategy and rebrand as ETHzilla Corporation.

The PIPE, priced at $2.65 per share, includes participation from more than 60 investors, among them Electric Capital, Polychain Capital, GSR, and Ethereum ecosystem leaders such as Robert Leshner (Compound), Tarun Chitra (Gauntlet), and Konstantin Lomashuk (Lido).

Proceeds will be primarily used to acquire ETH, positioning ETH as the company’s principal treasury reserve asset. Electric Capital will act as the external asset manager, introducing a yield-generation program that aims to outperform standard ETH staking by combining staking, lending, liquidity provisioning, and private agreements.

With ETH serving as the backbone of its balance sheet, 180 Life Sciences is signaling one of the boldest corporate treasury shifts to date, aligning itself with a growing trend of public companies integrating digital assets into their financial strategy.

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。